PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, ...
Wednesday was a good day for investors of biotech Arrowhead Pharmaceuticals (ARWR). Shares took off to the tune of 40% following the release of positive trial data. In the Phase 2 open-label trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results